A blood-based liquid biopsy can reliably detect cancer before conventional clinical diagnosis.
Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.
Causal mechanisms recorded for this claim. The State Warrant above remains the authoritative current assessment.
Detectable cancer signal as proxy for clinically meaningful early cancer. Blood-based ctDNA signal detects the presence of cancer-derived nucleic acids. This is a proxy for clinically meaningful early cancer — cancer that, if detected earlier, would produce better patient outcomes. The proxy gap exists because not all detectable cancers are clinically meaningful: some grow slowly, some would spontaneously regress, and some are already beyond the treatment benefit window even when "early." The measurement (ctDNA signal) is not the same kind of thing as the asserted object (cancer that benefits from earlier detection). This is a measurement validity bottleneck per RN-005: the proxy relationship between the blood signal and clinically meaningful early cancer requires independent validation through outcome data — specifically, whether patients whose cancers are detected by liquid biopsy have better survival outcomes than those detected conventionally. The NHS-Galleri RCT is the primary evidence-gathering mechanism for this validation.
Mortality outcome validation requires years of follow-up. The definitive evidence for whether earlier detection improves survival requires following participants from detection through treatment and long-term outcomes. NHS-Galleri's 2026 primary analysis measured late-stage cancer incidence, not mortality, and therefore cannot by itself close the record's outcome-validity gap. Mortality linkage or another adequately powered randomised mortality analysis remains subject to a longer biological-time validation lag.
Randomised mortality evidence following multi-cancer early detection. The event capable of moving this record decisively beyond FRAGMENTING is an adequately powered comparison showing whether screening reduces cancer-specific or all-cancer mortality without disproportionate overdiagnosis and downstream harm. NHS-Galleri's late-stage-incidence analysis is relevant stage-shift evidence but does not itself satisfy this attractor.
Historical narrative recorded for this claim. It does not override the current State Warrant.
Questions retained in this record. The current State Warrant may have narrowed or reframed earlier questions.
How should the record distinguish late-stage-incidence evidence from mortality evidence when stage shift is reported before sufficiently mature survival follow-up, and what mortality endpoint would be adequate to resolve the claim?
Raised 2024-01-15The pre-production observation identified early-stage sensitivity (24% for Stage I) as a critical gap. Does this gap constitute a measurement validity issue (ctDNA signal is an insufficient proxy at early stages) or a technological limitation (current assays lack sensitivity, which future methods will improve)? These have different implications for the claim's trajectory.
Raised 2024-01-15INST-005 is the eighth occurrence of anticipatory institutional evidence and the second instance of pre-validation commercial deployment (after FR-BT-0003 INST-005). The pattern of commercialising before definitive clinical evidence is twice confirmed in PROG-BT. Does this constitute a PROG-BT-specific commercial pressure dynamic, or is it a broader biotechnology sector pattern? This bears on whether the fifth anticipatory act type (undermining validation environment) belongs in RN-004 or in a PROG-BT programme note.
Raised 2024-01-15| Mutation | Date | Field | Prior value | Current value |
|---|---|---|---|---|
| M-009 | 2026-09-06 | description_restored | Legacy ingestion cutoffs: mechanisms:BN-001 | Source-restored complete descriptions |
| M-008 | 2026-08-28 | reference_corrected | Instance references absent; IN-002 cohort/date imprecise; IN-003/AS-001 derivative frame treated mortality as NHS-Galleri's primary endpoint; IN-005 transaction value and divestment account imprecise; IN-006 described a conference abstract as concurrent JCO publication | IN-001–IN-006 references recorded; cohort, endpoint, transaction and publication-status descriptions corrected |
| M-007 | 2026-06-27 | assessment_issued | — | ASSESSMENT-ISSUED |
| M-006 | 2026-06-27 | instances_logged | — | INSTANCES-LOGGED |
| M-005 | 2024-01-15 | diagnosis_confirmed | — | DIAGNOSIS-CONFIRMED |
| M-004 | 2024-01-15 | mechanisms_recorded | — | MECHANISMS-RECORDED |
| M-003 | 2024-01-15 | assessment_issued | — | ASSESSMENT-ISSUED |
| M-002 | 2024-01-15 | instances_logged | — | INSTANCES-LOGGED |
| M-001 | 2024-01-15 | record_created | — | RECORD-CREATED |